GC Biopharma, which had recorded an operating loss for 2 consecutive quarters, succeeded in turning a profit this quarter. GC Biopharma explained that the company has succeeded in doing so by increasing sales of highly profitable products and efficient execution of costs.

GC Biopharma also announced plans to accelerate its overseas business with a focus on blood derivatives. GC Biopharma explained that the company plans to release its immunoglobulin 10% for intravenous administration product within the second half of next year and speed up exports of its blood product plant in Indonesia.

Ends the 2nd quarter streak of operating losses...’Expansion of high-margin product sales + reduc

Kim, Jin-Gu(kjg@dailypharm.com)